Mimedx Group, Inc. (MDXG) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

Home SEC Filings Mimedx Group, Inc. (MDXG) 10-Q Quarterly Report Mon Jul 06 2020


Exhibit 99.1


MiMedx Announces Filing of 2018 Annual Report
Annual Report on Form 10-K includes Audited Financial Results for 2016 (restated), 2017 and 2018
2018 Net Sales of $359.1 million
Reflects Revenue Recognition on Cash Basis for all Years

MARIETTA, Ga., March 17, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2018 Annual Report, which includes the Company’s audited consolidated statements of operations, and stockholders’ equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.

Timothy R. Wright, MiMedx Chief Executive Officer, said: “The filing of our 2018 10-K is a significant milestone that repositions MiMedx for the future and reflects our commitment to serving urgent patient and physician needs. By instilling a culture of operational excellence, supportive of future growth and profitability, and making investments into the optimization of our Manufacturing, Research & Development, and Commercial organizations, we are positioning the Company to continue delivering evidence-based, advanced technologies that elevate the standard of care.”

MiMedx continues to focus on supporting the steadily growing advanced wound care market, including investment in both clinical programs and health economics research to demonstrate the cost effectiveness of our products. Commercial efforts are aimed at category awareness, illustrating the impact of untreated wounds, and refining our sales messaging platforms. Operationally, the Company is transforming its business by strategically enhancing each functional area; implementing measures for sustainable compliance and improvement; and optimizing manufacturing processing efficiencies that support the transition of clinical and regulatory parameters for regenerative medicine. Efforts are also underway to complete and file the annual report on Form 10-K for the year ended December 31, 2019. The Company plans to announce the date of its annual meeting of shareholders shortly after it files its annual report on Form 10-K for the year ended December 31, 2019.

Highlight of Key Metrics

•
2018 net sales of $359.1 million.
•
Restated net sales are $480.1 million from 2014-2016, representing a difference of $70.4 million compared to originally reported cumulative net sales of $550.5 million.
•
A significant portion of the restatement difference is due to revenue recognition when payment was received. Refer to “Recent Developments” below for more information.
•
Net loss of $30.0 million for 2018 reflects $51.3 million of investigation, restatement and related expenses.
•
2018 Adjusted EBITDA of $69.1 million1.




The following information was filed by Mimedx Group, Inc. (MDXG) on Wednesday, March 18, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Mimedx Group, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mimedx Group, Inc..

Continue

Rating

Learn More
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Legal
Mgmt Change
Other
Filter by Subcategory:
All
Expense
Earnings
Product
Income
Shares
Cash Flow
Other
Inside Mimedx Group, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

SEC Filing Financial Summary

Microsoft Excel Excel Download

Loading SEC Filing Financial Summary...

Material Contracts, Statements, Certifications & more

Mimedx Group, Inc. provided additional information to their SEC Filing as exhibits

SEC Filing Exhibit

Adobe PDF PDF Download

Loading SEC Filing Exhibit...

Ticker: MDXG
CIK: 1376339
Form Type: 10-Q Quarterly Report
Accession Number: 0001376339-20-000051
Submitted to the SEC: Mon Jul 06 2020 6:30:47 AM EST
Accepted by the SEC: Mon Jul 06 2020
Period: Sunday, March 31, 2019
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Insider Transactions
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/mdxg/0001376339-20-000051.htm

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account